Altamira Therapeutics (CYTOF) has delivered a -14.560% change over the past year, with a 52-week range between 0.050 and 0.148. What Is the Average Daily Trading Volume of Altamira Therapeutics (CYTOF ...
Joseph Chen, left, and Kavitha Yaddanapudi, University of Louisville immuno-oncology researchers, using the CyTOF instrument for cancer immunotherapy research. Cancer remains one of the greatest ...
Altamira Therapeutics Ltd (CYTOF) is making significant progress in its RNA delivery business, focusing on nanoparticle formulation and process development. The company has successfully developed ...
HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery ...
Good day and welcome to the Altamira Therapeutics’ Full Year 2024 Financial Results and Business Update Call. Today’s conference is being recorded. I would now like to hand the conference over to your ...
Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly increasing protein expression vs. linear mRNA Filed provisional ...
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for ...
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: ...
The milieu surrounding tumors is a complex mixture of immune cells, blood vessels, connective tissue cells, and extracellular matrix molecules that all exert a tremendous influence on the cancerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results